Mobile Application for Prescription Drug-Abuse Education (MAPDE) (MAPDE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03165175|
Recruitment Status : Completed
First Posted : May 24, 2017
Results First Posted : August 5, 2019
Last Update Posted : August 5, 2019
|Condition or disease||Intervention/treatment||Phase|
|Prescription Drug Abuse (Not Dependent)||Behavioral: prescription drug-abuse education smartphone application||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mobile Application for Prescription Drug-Abuse Education (MAPDE)|
|Actual Study Start Date :||May 22, 2017|
|Actual Primary Completion Date :||June 11, 2018|
|Actual Study Completion Date :||October 17, 2018|
Experimental: App + treatment as usual
The experimental group will be provided with the prescription drug-abuse education smartphone application in addition to treatment as usual. This educational mobile phone app focuses on helping military members reduce their risk for prescription drug misuse.
Behavioral: prescription drug-abuse education smartphone application
As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
No Intervention: Treatment as usual
The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
- Current Opioid Misuse Measure (COMM) [ Time Frame: Baseline and 1 month ]Mean COMM scale score as an indicator of risk for opioid prescription drug misuse. It measures 17 misuse behaviors over the past 30 days for those currently taking medications. Scores can range from 0-4 with higher scores indicating a worse outcome.
- Pain Medication Questionnaire (PMQ) Shortened Scale [ Time Frame: Baseline and 1 month ]Mean PMQ scale score as an indicator of prescription drug misuse. This 5-item scale was adapted from a brief scale previously used by Morasco and Dobscha (2008), which is actually a subset of the Pain Medication Questionnaire (PMQ) scale (Adams et al., 2004). The original scale was created to screen for prescription drug misuse among chronic pain patients undergoing opioid therapy, and the shortened scale was created for use among a military veteran population. Scale ranges from 1-5 with higher scores indicating a worse outcome.
- Prescription Drug Misuse-related Attitudes [ Time Frame: Baseline and 1 month ]A scale score for items from the 8-item Prescription Drug Attitudes Questionnaire (PDAQ; Bodenlos et al., 2014), which were adapted by the investigators for the military. The scores range from 1-5 with higher scores indicating a worse outcome.
- Prescription Drug Misuse-related Knowledge [ Time Frame: Baseline and 1 month ]Mean number of correct knowledge items. Twenty-three multiple choice knowledge items assessed the participant's level of knowledge of the definition of misuse and related educational points. Possible range is 0-23 with higher scores reflecting higher knowledge levels.
- Preparedness to Talk About Misuse [ Time Frame: Baseline and 1 month ]Two investigator-developed items were used to assess the level of preparedness to talk to others (i.e., chain of command, doctor) about concerns related to one's own possible prescription drug misuse. The scale ranged from 1-5 with higher scores indicating a better outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03165175
|United States, California|
|Naval Health Research Center|
|San Diego, California, United States, 92106|
|Principal Investigator:||Suzanne L Hurtado, MPH||Naval Health Research Center|